Inclusion Criteria:

- Histologically or cytologically confirmed cutaneous malignant melanoma

- Must meet one of the following criteria:

- Clinical evidence of metastatic disease

- Unresectable regional lymphatic disease

- Extensive in transit recurrent disease

- Measurable disease

- At least 20 mm by conventional techniques OR at least 10 mm by spiral computed
tomography (CT) scan

- No known brain metastases

- No ocular melanoma

- Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2

- Performance status - Karnofsky 60-100%

- More than 6 months

- White blood cells (WBC) at least 3,000/mm^3

- Absolute neutrophil count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

- No clinical evidence of coagulopathy

- Bilirubin =< 2.0 mg/dL (3.0 mg/dL for patients with Gilbert's disease provided
patient is stable and asymptomatic)

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) no greater than 2.5
times upper limit of normal (ULN)

- Prothrombin time (PT)/International normalized ratio (INR) less than 1.5

- Creatinine =< 1.5 mg/dL

- Creatinine clearance at least 60 mL/min

- Protein < 1,000 mg on 24-hour urine collection for patients with proteinuria >= 1+

- No symptomatic congestive heart failure

- No unstable angina pectoris

- No cardiac arrhythmia

- No history of thrombosis (e.g., deep vein thrombosis), unless the following criteria
are met:

- INR in normal range (usually 2-3) AND on a stable dose of warfarin or low
molecular weight heparin

- No active bleeding or pathologic condition that would confer a high risk of
bleeding (e.g., known varices or tumor involving major vessels)

- No uncontrolled hypertension

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior allergic reactions to compounds of similar chemical or biologic composition
to bevacizumab or interferon alfa

- No ongoing or active infection

- No other concurrent uncontrolled illness

- No psychiatric illness or social situation that would preclude study compliance

- Human immunodeficiency virus (HIV) allowed provided otherwise well

- At least 4 weeks since prior adjuvant interferon alfa

- No prior interferon alfa for metastatic disease

- No prior cytokine therapy for metastatic disease (e.g., high-dose interleukin-2
[IL-2])

- Prior IL-2 allowed for patients randomized to arm III only

- No prior investigational antiangiogenic agents

- No more than 1 prior chemotherapy regimen for metastatic disease

- At least 4 weeks since prior chemotherapy and recovered

- At least 4 weeks since prior radiotherapy and recovered

- No other concurrent investigational agents